The present relates to compounds of the formula (1): in which R1 is Hydrogen, Lower alkyl, halogen, alkoxy alkyl substituted by Halogen, Lower, Lower, Lower alkoxy substituted by Halogen, Nitro, cyano, cycloalkyl - CH2 - C3 - 6, 6 - or cycloalkyl C3, C3 - CH2 - cycloalkyl - 6 - O - (CH2) 2 - or lower alkyl, S (OR) 2ch3, sedan, - C (o) nH Lower alkyl, phenyl, or pirimidinilo,Optionally substituted by Halogen or lower alkoxy substituted benzyl oxetanilo is, or furanilo； M is 1 or 2； ar is aryl or heteroaryl, chosen from the group formed by phenyl, naphthyl, pirimidinilo, pyridinyl, benzotiazolilo, quinolinilo, quinazolinilo, benzo [d] [1.3] dioxolilo, 5,6,7,8-tetrahydro - quinazolinilo, pirazolilo, pirazinilo, and piridazinilo 1,3,4 - oxadiazolilo； and is a link ch2ch2 - CH2 -, -, -, - ch (Cf3) - or - ch (CH3)； R2 is Hydrogen or lower alkyl； n is Cr and R is Hydrogen or； Halogen or lower alkyl, cyano,； R is Hydrogen or Halogen； Co N condition that if R is Halogen, then B is CH or CH； n； n is the Number 0,1 or 2； X is a Link, - CH2 - or - or - or acid Addition salts of pharmaceutically Active products. It has been found that the compounds of the formula (1) have good Affinity to receptors associated with Trace amines (Taars), in particular with TAAR1.The compounds can be used for the treatment of depression, Anxiety Disorders, bipolar disorder, Attention deficit hyperactivity disorder (ADHD), stress disorders, psychotic disorders, including schizophrenia, disease The Neurological, for example Parkinson's disease, neurodegenerative disorders,Alzheimer's disease, Epilepsy, Migraine, hypertension, Substance Abuse Disorders and Metabolic Disorders, for example food intake, diabetes, complications of diabetes, obesity, dyslipidemia, and disorders of consumption and assimilation Nerg u00eda, disruption and malfunction of temperature homeostasis.The circadian rhythm and Sleep Disorders and cardiovascular disorders.La presente se refiere a compuestos de la fórmula (1) en la qu
